TP53 and breast cancer: This degrader, employing an RNA aptamer, effectively inhibited proliferation in various lung and breast cancer cells with p53-R175H mutation, while leaving wild-type p53 and other p53 mutants unaffected and promoting p53 downstream effectors.470 Moreover, the reactivated p53 was observed in PROTACs targeting MDM2 or BRD4, as discussed in the relevant section.